Cyclic neutropenia

X4 Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host a Conference Call and Webcast on August 4, 2022

Retrieved on: 
Tuesday, July 26, 2022
WHIM, United, Medication, GLOBE, WM, WHIM syndrome, Immunodeficiency, Research, Partnership, B-cell lymphoma, Immune system, Safety, Cancer, Webcast, Company, Patient, Cyclic neutropenia, Biology, Therapy, CXCR4, Pharmaceutical industry

The Company will host a conference call and webcast on the same day at8:30 a.m. ETto discuss these financial results and business highlights.

Key Points: 
  • The Company will host a conference call and webcast on the same day at8:30 a.m. ETto discuss these financial results and business highlights.
  • The conference call can be accessed by dialing 1-855-327-6837 fromthe United Statesor 1-631-891-4304 internationally, followed by the conference ID: 10019589.
  • The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals website at www.x4pharma.com .
  • Following the completion of the call, a webcast replay of the conference call will be available on the website.

X4 Pharmaceuticals Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones

Retrieved on: 
Wednesday, July 20, 2022
WHIM, Traffic barrier, GLOBE, WM, Importance, MYD88, U.S. Securities and Exchange Commission, CN, Orphan, WHIM syndrome, Wart, SEC, Immunodeficiency, Research, Forward-looking statement, Partnership, Leukemia, Toxicology, Workforce, Private Securities Litigation Reform Act, NDA, Lymphoma, B-cell lymphoma, Patent, Risk, Immune system, Safety, COVID-19, Cancer, Achievement, Clinical trial, FDA, Security (finance), Patient, Cyclic neutropenia, Biology, Therapy, CXCR4, IND, Pharmaceutical industry, Infection, Hypogammaglobulinemia

BOSTON, July 20, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small-molecule therapeutics to benefit people with diseases of the immune system, today announced an update to its strategic priorities that includes streamlining resources to focus on advancing its lead clinical candidate, mavorixafor, in WHIM syndrome and other chronic neutropenic disorders, while progressing its clinical and pre-clinical oncology programs only via potential partnership(s).

Key Points: 
  • X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company leading the discovery and development of novel therapies for people with diseases of the immune system.
  • Our lead clinical candidate is mavorixafor, a first-in-class, small molecule antagonist of chemokine receptor CXCR4 that is being developed as a once-daily oral therapy.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
  • Any forward-looking statements in this press release are based on management's current expectations and beliefs.